Project UpdateJul 7, 2026, 07:44 AM
Clearmind Medicine advances intranasal MEAI delivery for AUD
AI Summary
Clearmind Medicine Inc. announced continued progress in evaluating intranasal delivery of its proprietary MEAI (5-Methoxy-2-aminoindane) as a potential additional route of administration for alcohol use disorder (AUD). Initial formulation feasibility studies successfully demonstrated that MEAI can be incorporated into the formulation, resulting in a stable and fully soluble solution. This development aims to enhance therapeutic potential and improve patient experience for AUD, which remains a significant unmet medical need.
Key Highlights
- Successfully evaluated intranasal delivery of MEAI for alcohol use disorder (AUD).
- Formulation feasibility studies confirmed MEAI's compatibility and suitability for intranasal administration.
- Studies resulted in a stable and fully soluble MEAI solution for intranasal delivery.
- MEAI is Clearmind's lead proprietary therapeutic candidate for addiction-related disorders.
- Company holds nineteen patent families, including 32 granted patents.
- Aims to improve patient experience, convenience, and therapeutic performance for AUD.
Price Impact
More from CMND